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We report the prevalence and characteristics of
Salmonella strains resistant to ciprofloxacin and extended-
spectrum cephalosporins in Taiwan from January to May
2004. All isolates resistant to extended-spectrum
cephalosporins carried blaCMY-2, and all ciprofloxacin-resist-
ant  Salmonella enterica serotype Choleraesuis isolates
were genetically related. 
R
esistance to extended-spectrum cephalosporins
(ESCs) or fluoroquinolones in Salmonella enterica
has become a global concern (1). ESC resistance in
Salmonella strains is usually due to the production of plas-
mid-mediated extended-spectrum β-lactamases (ESBLs)
or AmpC β-lactamases, and among these β-lactamases, the
CMY-2 AmpC enzyme has been reported most often (1–3).
Resistance to fluoroquinolones in Salmonella strains is
usually due to the accumulation of mutations in the
quinolone resistance–determining regions (QRDRs) of
DNA gyrase genes (1,4,5). Resistance to both ESCs and
fluoroquinolones remains extremely rare in salmonellae.
In Taiwan, increasing resistance to fluoroquinolones
and the emergence of CMY-2–producing ESC-resistant
strains in salmonellae have been noted (3–6). The emer-
gence of Salmonella strains resistant to both ceftriaxone
and ciprofloxacin was reported more recently in Taiwan
and may pose a serious therapeutic problem (7,8). We con-
ducted the present study to investigate the prevalence and
characteristics of Salmonella strains resistant to
ciprofloxacin and ESCs in Taiwan. 
The Study
From January to May 2004, a total of 600 Salmonella
isolates from 585 patients were obtained from 5 medical
centers and 14 district hospitals throughout Taiwan; these
isolates were serotyped with commercial antisera (Difco,
Detroit, MI, USA). The 4 most common serotypes of
Salmonella enterica (Enteritidis, Typhimurium, Stanley,
and Choleraesuis) accounted for 66.8% of all isolates. Two
isolates were untypeable, and the remainder were typed
into 42 serotypes (data not shown), which were each rep-
resented by 1 to 23 isolates.
MICs of antimicrobial agents were determined by the
agar dilution method (9). Resistance to ciprofloxacin (MIC
>4 µg/mL) was seen in 50 (8.3%) isolates (Table l); 20
(3.3%) were resistant (MICs ranging from 8 to >64
µg/mL) to ceftazidime, ceftriaxone, cefotaxime, or aztre-
onam (Table 2); 6 isolates showed decreased susceptibili-
ties to 1 or 2 of the 4 ESCs (MICs 0.5–2 µg/mL); 10
(1.7%) isolates were resistant to both ciprofloxacin and
ESCs.  S. Choleraesuis had high rates of resistance to
ciprofloxacin (84.4%), ESCs (17.8%), and both (17.8%).
None of the 26 Salmonella isolates with resistance or
decreased susceptibility to ESCs produced ESBL, accord-
ing to the double-disk synergy method (10). Among the 20
ESC-resistant isolates, 10 isolates were ciprofloxacin-
resistant, 4 isolates showed decreased susceptibility to
ciprofloxacin (MIC 0.25–1 µg/mL) and resistance to
nalidixic acid, and 6 isolates were susceptible to
ciprofloxacin and nalidixic acid (Table 2). All 20 ESC-
resistant isolates were susceptible to cefepime (MIC <0.03
µg/mL) and imipenem (MIC <1 µg/mL), and 17 isolates
were resistant to >1 non–β-lactam agent. 
All 20 ESC-resistant isolates expressed a β-lactamase
of pI 9.0 by isoelectric focusing (3,11); 11 of these isolates
expressed an additional pI 5.4 β-lactamase (Table 2).
blaCMY-2 was detected in all ESC-resistant isolates. blaTEM-
1 was detected in the 11 isolates with the pI 5.4 β-lactamase
by polymerase chain reaction (PCR) and sequence analy-
ses with the primers for the entire blaTEM-related and
blaCMY-2-related structural genes (2,3).
The QRDR sequences of gyrA, gyrB, parC, and parE of
the 20 ESC-resistant Salmonella isolates were determined
by PCR and sequence analyses (5). All 10 ciprofloxacin-
resistant isolates showed 2 mutations at the Ser-83 and
Asp-87 codons in gyrA and a single mutation at the Ser-80
codon in parC (Table 2). Four isolates with decreased sus-
ceptibility to ciprofloxacin had a single mutation at either
the Ser-83 or the Asp-87 codon in gyrA. All 20 ESC-resist-
ant isolates showed no mutations in the QRDRs of gyrB
and parE.
ESC resistance was transferred from 18 of the 20 ESC-
resistant Salmonella isolates to Escherichia coli C600 in
the liquid mating-out assay (3,12). All transconjugants
showed decreased susceptibilities to the 4 ESCs tested
(MICs 16–64 µg/mL) and cefoxitin (MIC 64–128 µg/mL)
and were susceptible to all non–β-lactam agents tested. A
pI 9.0 vz β-lactamase and blaCMY-2 were detected by iso-
electric focusing and PCR assays, respectively, in all
transconjugants. Restricted by the endonuclease EcoRI,
the 18 transferred plasmids produced 9 major restriction
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ther divided into 4 and 2 subtypes, respectively. blaCMY-2 on
the transferred plasmids was demonstrated by Southern
hybridization with the blaCMY-2 probe.
The 38 ciprofloxacin-resistant S. Choleraesuis isolates
were genotyped by pulsed-field gel electrophoresis on a
CHEF Mapper apparatus (Bio-Rad Laboratories, Hercules,
CA, USA) according to the PulseNet protocol (13).
Banding patterns generated by XbaI restriction were com-
pared with BioNumerics software (Applied Maths,
Kortrijk, Belgium). The 38 isolates showed a close rela-
tionship (Dice correlation coefficient of 90%) and had only
1 pulsotype, based on Tenover criteria (Figure 2) (14). The
pulsotype was divided into 7 pulsosubtypes, among which
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played the same pulsosubtypes (IA or IC) as ESC-suscep-
tible isolates (Table 1 and Figure 2).
Conclusions
We describe the prevalence of resistance to
ciprofloxacin and ESCs among salmonellae isolated from
January to May 2004 in Taiwan. We found widespread
resistance of Salmonella isolates to both ESCs and
ciprofloxacin; high prevalence of resistance to
ciprofloxacin, ESCs, and both in S. Choleraesuis; and
widespread prevalence of CMY-2–producing Salmonella
isolates of various serotypes in Taiwan. 
The prevalence of Salmonella isolates resistant to both
ceftriaxone and ciprofloxacin may pose a therapeutic prob-
lem. CMY-2 is one of the AmpC enzymes, which are usu-
ally less active against cefepime and cefpirome than
ESBLs (15). Accordingly, we have used cefepime to suc-
cessfully treat several patients infected with CMY-2–pro-
ducing and ciprofloxacin-resistant S. Choleraesuis (8).
Therefore, AmpC-producing strains should be differentiat-
ed from ESBL-producing strains by phenotypic or geno-
typic methods when ESC-resistant Salmonella strains are
isolated in the clinical microbiology laboratory (15). 
The ciprofloxacin-resistant rate in S. Choleraesuis in
Taiwan has been >60% since 2001; the high prevalence
was mainly due to clonal spread of resistant strains (4–6).
The ciprofloxacin-resistant rate in S. Choleraesuis in this
report (84.4%) was higher than those reported previously
(<70%) (4–6). blaCMY-2 in Salmonella in Taiwan was first
reported in 2 S. Typhimurium strains isolated in 2000 (3).
The first reported S. Choleraesuis strain with blaCMY-2 was
a ciprofloxacin-resistant strain isolated in 2002 (7). All our
38 ciprofloxacin-resistant S. Choleraesuis isolates, includ-
ing 8 ESC-resistant isolates, were genetically related.
Moreover, we found possibly unrelated blaCMY-2-positive
plasmids (lanes 3, 4, 7, 8, 10, and 11 in Figure 1) among
closely related isolates (Figure 2). These data together sug-
gest that the development and rapidly increasing preva-
lence of ESC and ciprofloxacin resistance in S.
Choleraesuis in Taiwan might result from the extremely
high prevalence of ciprofloxacin resistance followed by
Drug-resistant Salmonella, Taiwan
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Figure 1. EcoRI restriction patterns of transferred CMY-2-encoding
plasmids of 18 Salmonella isolates. The result of the hybridization
assay with the blaCMY-2 probe labeled with digoxigenin (Roche
Molecular Biochemicals, Mannheim, Germany) is shown below
the gel, and arrowheads indicate the locations of the restriction
fragments that were hybridized. Lanes 2-21, plasmids from
transconjugants of Salmonella isolates NB04.022, SB04.003,
NL04.050, SA04.028, CG04.039, SG04.039, SG04.042,
SE04.006, SG04.047, SE04.005, NG04.011, NG04.016,
NG04.018, NC04.001, NC04.002, NC04.003, NC04.004, and
CE04.015; lanes 1 and 22, molecular marker II (Roche Molecular
Biochemicals); lanes 12 and 13, a 1-kb molecular marker
(Promega Co., Madison, WI, USA)
Figure 2. Dendrogram (left) obtained from cluster analysis of
XbaI-generated macrorestriction patterns of 38 ciprofloxacin-
resistant  Salmonella enterica serotype Choleraesuis (right).
Asterisks indicate extended-spectrum cephalosporin-resistant
isolates. A percent scale of similarity is shown above the dendro-
gram. Pulsed-field gel electrophoresis (PFGE) types are shown
between the gel and the dendrogram. H9812, S. enterica
serotype Braenderup strain H9812, which was used as reference
size marker.the horizontal transfer of blaCMY-2 into ciprofloxacin-resist-
ant epidemic strains rather than from the spread of a clone
that had been resistant to ciprofloxacin and ESCs.
All our ciprofloxacin-resistant Salmonella isolates test-
ed had mutations in the QRDRs of gyrA and par, a finding
consistent with previously reported results (1,4,5). The
rates of ciprofloxacin resistance in the 3 most common
serotypes, Enteritidis, Typhimurium, and Stanley,
remained very low (0%–0.6%). Six of 11 ciprofloxacin-
resistant isolates in the group of uncommon serotypes
belonged to serotype Schwarzengrund and accounted for
42.9% of all serotype Schwarzengrund isolates. Thus, the
high rate (5.5%) of ciprofloxacin resistance in this group
was in part due to the high prevalence of ciprofloxacin
resistance in serotype Schwarzengrund.
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